Pharmafile Logo

transcreation

- PMLiVE

Scotland becomes first part of UK to screen all newborn babies for SMA

The screening is part of a two-year evaluation funded by the Scottish government and Novartis

- PMLiVE

RedSail Technologies appoints Joy Neely as Chief Growth Officer

Neely previously worked at Medvantx, Roche and Eli Lilly

- PMLiVE

Novartis agrees on potential $3bn deal to buy Synnovations’s breast cancer treatment

The oral drug is currently being evaluated for breast cancer and other advanced solid tumours in a phase 1/2 study

- PMLiVE

Prime appoints David Hogben as SVP, Omnichannel Strategy & Delivery

Hogben has previously worked across the US and global markets

- PMLiVE

Leading with Heart: Why Vulnerability is a Force Multiplier

In a world that often prizes "macho" decisiveness, Dr. Lobna Salem (CMO at Viatris) and Dr. Amrit Ray (Board Chairman and former Pfizer executive) are advocating for a more human...

Medscape Education

- PMLiVE

Department of Health and Social Care and partners launch new funding initiative

The DHSC, along with a UK government department and Wellcome, aims to tackle urgent infectious disease threats

- PMLiVE

Biologos appoints Hetal Patel as CEO

The appointment coincides with Biologos’ 50th anniversary

- PMLiVE

Almirall celebrates new offices in China to advance innovation in dermatology

The company’s R&D and commercial expertise represent valuable capabilities for future Chinese partners

- PMLiVE

Lucid Group appoints former Pfizer R&D leader Rod MacKenzie as Board Chair  

Lucid’s US Medical Affairs division unveils new proprietary insights tools to expand advisory capabilities 

- PMLiVE

Cardiology Education in the Age of AI: Join Medscape at ACC 2026

  As medical knowledge now doubles every 73 days, the challenge for cardiology clinicians has shifted from finding information to mastering precision. At the American College of Cardiology (ACC) 65th...

Medscape Education

Lucid Group Appoints Former Pfizer R&D Leader Rod MacKenzie, CMG, PhD, as Board Chair to Drive Next Phase of Global Growth and Innovation

Appointment marks a pivotal step in Lucid’s next phase of growth, strengthening its ability to translate complex science into real-world impact. Lucid’s US Medical Affairs division unveils new proprietary insights...

Lucid Group Communications Limited

- PMLiVE

Atrogi moves forward in phase 1 trial for oral candidate to improve metabolic and muscle health

First-in-class oral therapy mimics the effects of exercise with broad potential as a novel treatment for muscle-sparing weight loss

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links